

Advertisement
Fisher Investments



7 Retirement Investment Strategies for Australians.

[Read Today's Paper](#)

[Tributes & Notices](#)

11:07am Wednesday, September 2nd, 2026

[Toowoomba](#)
[City](#)

Today 10 °/
23 ° >

The Chronicle
We're for you

Hi, George

[My News](#)

[Today's Paper](#)

[Toowoomba](#)

[World](#)

[Sport](#)

[Business](#)

[Opinion](#)

[Education](#)

[Lifestyle](#)


[Entertainment](#)

[Puzzles](#)



[Business](#) [Stockhead](#)

Biocurious: It's spring, when a young




"Ooh that's nice but I would rather a statistically significant, randomised, double blinded trial readout." Pic: Getty Images

Modest clinical trial results are pending from Recce, Paradigm and Actinogen Medical

- The results are likely to make or break the companies' fortunes
- Alzheimer's drug developer Actinogen mulls a potential 'plan B' depression trial

Spring has sprung and what's not to love? Swooping magpies, hayfever and torrential rain notwithstanding, of course.

As well as increasing the ardour of animal species across the board, the season of reproduction has piqued the passion of investors awaiting key late-



Stockhead

ASX sector in red tails in July with health care best performer

The S&P/ASX 200 rose 1.54% in August as healthcare popped 19% to be top the performing

Paradigm tackles huge unmet need



similar reviews at the 20% and 50% mark.

Stockhead

Pilbara emerges as next copper frontier

The company confirmed a September timeline for the interim readout.

The Pilbara has emerged as a copper growth story in Australian mining, with two mines

heading towards construction. "And there's more to come.

But the timing remained "subject to completion of the required data cleaning, biometrics and independent review processes."



carried out across 37 sites, 41 of them in the US and 12 in Australia.

Stockhead

The primary endpoint is the change in pain intensity at day 112, as per

Weekly phases of SW antimony as CPO hunts Chilean copper

Red Mountain fires up the rig for maiden antimony drilling at Armidale, with Culpeo set to

The interim analysis covers 50% of participants.

The idea of Zilecul is to reduce the inflammation involved in knee OA. Zilecul



Stockhead

The study road tests the company's Recce 327 gel (R327G), for diabetic foot

Closing Bell: Spring is here, ASX slips and money costs too much

The ASX starts spring on the back foot as soaring bond yields, rate-hike nerves and falling

The need is apparent, given Indonesia's high diabetes rate.



Stockhead

In May this year Recce signed a non-binding term sheet with a "leading

Middle Eastern pharma company" for a ten-year, exclusive multi-country

LTR Pharma forges testosterone expansion

licensing deal.

LTR Pharma has added testosterone to its erectile dysfunction repertoire, via an exclusive

agreement with Marius Pharmaceuticals Inc of the US.

Meanwhile, Recce is carrying out an Australian-based phase III DFI trial. The

study aims for Australian and US approval.

Last month an ethics committee approved a trial protocol amendment, which

enables the addition of a randomised, active-controlled, non-inferiority study

arm.

The 208 patients receive either R327G, or one of four physician-selected

antibiotics for comparison.



Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.

[Follow](#)

Actinogen eyes Alzheimer's breakthrough
The company plans an interim analysis at the 104-patient mark. This is likely to occur in late 2027 or early 2028.

The ASX slipped this morning as war tensions fired up oil, housing sagged again and Beetaloo finally started pumping shale gas.

“R327G has the potential to become the first standard of care used by leading GPs in the GPR,” said

My News Feed [Read More >](#)



Blood spilt as chair directors ousted at iconic Aussie company
In its pursuit of a better treatment for Alzheimer's disease, Actinogen is comforted by late January's 'utility' interim analysis which showed that continuing the pivotal trial would be – well – far from pointless.

Mayfair Hotel to be transformed after \$75m sale

Digital air traffic control towers not fit for WFH, says Airservices boss

Dubbed Xanamia, the pivotal phase IIb/III trial road tests Xanamem (emstedastat).

Good Morning Geelong



That's not a Holden Special Vehicle, but a cortisol-producing enzyme expressed in parts of the brain governing memory and mood.

Why your next social media scroll could look very different
In its full year results last Thursday, Actinogen confirmed the study remained on track for topline final results in November.

'Not spectators': How a pledge led to final glory

Man with knife arrested for alleged \$1700 Geelong theft spree

The company reports that 89% of participants (108) have moved on to an open-label extension study.

RECOMMENDED TO FOLLOW

The good news is that as people are on the drug for longer and we are not

Police Courts Toowoomba

Toowoomba

Council

Development

Toowoomba

Gourlay

Community

Should the study pass master, Actinogen has agreed with the FDA and the European regulator on a streamlined further placebo-controlled pivotal trial of xanamem.

Trending now


Read More

“I’m feeling quite good about our program,” Gourlay says.

North America

Celebrity Life

Tragic detail after bank executive stabbed to death in Times Square



Shocking vandals target Dolly Parton’s



He stresses the trial relies on clinical outcomes – read: patient improvement rather than high falutin’ biomarker measures (our words).

QLD News

Premier’s plotting overhaul set to turbocharge One Nation



Royals

Meghan faces hiring crisis over ‘rude’ interview claims



In July the peer-reviewed British Journal of Psychiatry published Actinogen’s separate phase II proof-of-concept study.

Police & Courts

Predator’s playbook: How Doc abused boys using cognitive impairment



Commercial Real Estate

Man sues Bunnings in shock \$6m fight



In short, the journal opined the drug was “worthy of further investment”

The Butters bounty: Gourlay says an Alzheimer’s depression treatment



“far and away” more valuable than a

Royals

Former prince Andrew accused of ‘sex crimes in the US



But the company is open to pursuing a trial of depression in Alzheimer’s patients.


Tennis star’s US Open meltdown



“We are not saying we will or won’t do it,” he says.

Bank’s sad call: \$211k

“Maybe we can do a trial in older patients with perhaps outside not.



“If we could get that antidepressant activity as a feature for the drug into the prescribing information locally, that would be a really nice boost to the value of the molecule.”

He says the current interest in psychedelics highlights the need for new depression treatments beyond the current selective serotonin reuptake inhibitors (SSRIs, such as Prozac).

Gourlay dubs the chances of a complete Alzheimer’s flop as unlikely, “as we have so much data showing the activity of the drug in the brain”.

The company posted a full-year net loss of \$15.3m, having incurred \$19m of R&D costs. With \$16m in the bank, the company is well funded into 2027.

“If we found ourselves in a sticky situation, we have the time and the money and the right people to sort that out.”

Actinogen shares have blipped 48% year on year, but more recently shareholders have kept a lid on their excitement.

“Every CEO says we are hopelessly undervalued, but the net present value of a positive result is enormously higher than our current valuation,” Gourlay says.

A.k.a: 'we're dirt cheap, fill ya wellies'.

And – no - we are not licensed financial advisers.

Originally published as [Biocurious: It’s spring, when a young man’s fancy lightly turns to ... clinical trial results](#)

Advertisement

Membership

Group/Corporate Subscriptions

Today's Paper

Newsletters

My Tributes

About Us

About Us

Meet the Team

Job Opportunities

Code of Conduct

Subscription FAQs

Subscription terms

Financial Hardship Policy

Contact Us

Help & support

Story Tips

FAQs

Standards of practice

Letter to the Editor

Licensing & Reprints

Advertise with us

Our News Network

Courier Mail

Herald Sun

The Daily Telegraph

The Advertiser news.com.au

Gold Coast Bulletin

The Cairns Post

Townsville Bulletin

NT News

The Mercury

Geelong Advertiser

The Weekly Times

CODE Sports

Our Partners

Buy Search Sell Classifieds

Foxsports

Hipages

Kayo

My Tributes

Punters odds.com.au

racenet.com.au

News24 Australia

Coupons

Our Apps





A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network. Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEST (GMT +10). Powered by WordPress.com VIP

[Privacy policy](#)

[Relevant ads opt-out](#)

[Cookie policy](#)

[Terms of use](#)